By contrast, there was a negligible increase in survival among carriers of BRCA1 and BRCA2 aged over 35 years with luminal breast cancer in exon 11 who underwent any secondary prevention strategy compared with surveillance. The gene discussed is BRCA1; the disease is breast carcinoma.